Janaayo 22, 2025, "Daawada Dabeecadda" waxay daabacday natiijooyinka Akeso si madax-bannaan u samaysay cadonilimab antibody bispecific ah oo PD-1/CTLA-4 ah oo lagu daray oxaliplatin iyo capecitabine si loogu daaweeyo adenocarcinoma-ka aan la tirtiri karin ee maxalliga ah ama isgoyska caloosha ama caloosha (G/GEJ) ee daraasad caafimaad oo wejiga III ah (COMPASION-15/AK104-302).Natiijooyinka daraasadda COMPASION-15 waxaa hore loogu soo bandhigay afka shirkii sanadlaha ahaa ee Ururka Mareykanka ee Cilmi-baarista Kansarka (AACR) ee 2024.
Daraasaddan waxay ahayd mid aan kala sooc lahayn, laba-indhoole ah, oo placebo-xakamaysan oo wejiga 3aad ah. Bukaannada u qalma waxay ahaayeen dad waaweyn oo qaba adenocarcinoma G/GEJ oo aan la daaweyn, aan la tirtiri karin, heer deegaan ah oo horumarsan ama metastatic ah. Bukaannada waxaa loo kala soocay 1:1 si loo siiyo cadonilimab (10 mg kg−1 saddexdii toddobaadba mar) ama placebo iyo kiimoterabiga (3dii toddobaadba mar). Ujeeddada ugu weyn waxay ahayd badbaadada guud (OS) ee dadka loogu talagalay in lagu daweeyo (heerka muhiimadda hal-dhinac ah, P = 0.025). Dhibcaha labaad waxaa ka mid ahaa OS bukaanada leh dhibco togan oo isku dhafan oo PD-L1 ah ≥5, badbaadada aan horumarka lahayn, heerka jawaab celinta ujeeddada leh, muddada jawaabta iyo badbaadada. Laga bilaabo 18 Agoosto 2023, 610 bukaan oo ka kala yimid 75 xarumood oo waxbarasho ayaa loo kala soocay cadonilimab (n = 305) ama placebo (n = 305). Iyadoo la raacayo celcelis ahaan 18.7 bilood, kooxda cadonilimab waxay lahayd OS dhexdhexaad ah oo aad u dheer (14.1 marka loo eego 11.1 bilood; saamiga khatarta (HR) 0.66; 95% isku-kalsoonaanta muddada (CI) 0.54–0.81; P < 0.001) marka loo eego kooxda placebo. Dhibcaha ugu horreeya ayaa la gaaray. Badbaadada dhexdhexaadka ah ee aan horumarka lahayn waxay ahayd 7.0 bilood marka loo eego 5.3 bilood (HR 0.53, 95% CI 0.44–0.65). OS dhexdhexaad ah ee bukaanada leh dhibcaha togan ee isku dhafan ee PD-L1 ≥5 waxay ahayd 15.3 bilood marka loo eego 10.9 bilood (HR 0.58, 95% CI 0.41–0.82). Heerka jawaabta ujeeddada ah wuxuu ahaa 65.2% marka loo eego 48.9% iyadoo muddada dhexdhexaadka ah ee jawaab celinta ay tahay 8.8 bilood marka loo eego 4.4 bilood. Dhacdooyinka xun ee la xiriira daaweynta ee heerka ≥3 waxay ka dhaceen 65.9% kooxda cadonilimab iyo 53.6% kooxda placebo, kuwa ugu badanna waxay ahaayeen tirada platelet-ka oo yaraatay, tirada neutrophil oo yaraatay iyo dhiig la'aan. Inta badan dhacdooyinka xun ee la xiriira difaaca jirka waxay ahaayeen heerka 1 ama 2. Lama arag calaamado cusub oo badbaado ah. Cadonilimab iyo kiimoterabiga ayaa si weyn u hagaajiyay OS iyadoo leh astaan badbaado oo la maareyn karo bukaanada qaba adenocarcinoma G/GEJ oo horumarsan.
Cirbadda Cadonilimab waa daawo cusub oo heerka koowaad ah oo loogu talagalay daaweynta difaaca jirka ee PD-1/CTLA-4 oo heer sare ah oo gudaha lagu sameeyay. Juun 29, 2022, Cadonilimab waxaa ansixiyay NMPA ee Shiinaha si loogu daaweeyo bukaanada kansarka afka ilmo-galeenka ee soo noqnoqda ama ka soo kabanaya kansarka afka ilmo-galeenka (R/M CC) ee horumaray ama ka dib kiimoterabiga ku salaysan platinum. Sebtembar 2024, tilmaam cusub oo loogu talagalay cadonilimab ayaa loo ansixiyay daaweynta safka koowaad ee bukaanada qaba adenocarcinoma-ka caloosha ama caloosha ee aan la jari karin ama ka soo baxayn gudaha, iyadoo lagu darayo fluoropyrimidine iyo kiimoterabiga ku salaysan platinum. Waqtigan xaadirka ah, codsiyada cusub ee daawada Cadonilimab oo lagu daray kiimoterabiga ku salaysan platinum, oo leh ama aan lahayn bevacizumab, si loogu daaweeyo safka koowaad ee kansarka afka ilmo-galeenka ee joogtada ah, soo noqnoqda, ama ka soo baxa kansarka afka ilmo-galeenka ayaa waxaa aqbalay CDE. Intaa waxaa dheer, taxane daraasado caafimaad ah, oo ay ku jiraan tijaabadii wejiga III ee daaweynta dheeraadka ah ee bukaanada qaba khatarta sare ee soo noqoshada ka dib marka la gooyo daaweynta kansarka beerka, ayaa si hufan loo sameynayaa.
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Email：myimmnet@163.com
Tixraacyada
https://www.nature.com/articles/s41591-024-03450-4
Waqtiga boostada: Febraayo-21-2025